Provided By GlobeNewswire
Last update: Mar 17, 2025
Antitumor activity observed with confirmed partial responses in 50% of patients
at highest dose tested to date, across multiple tumor types
PLN-101095 was generally well tolerated across all doses
Read more at globenewswire.comNASDAQ:PLRX (7/25/2025, 3:53:06 PM)
1.565
-0.03 (-1.57%)
Find more stocks in the Stock Screener